Dr John M

cardiac electrophysiologist, cyclist, learner

  • Home
  • About
    • About Me
    • About the Blog
      • General Cardiology and Internal Medicine
    • Six Reasons why I Blog
    • What’s Electrophysiology?
    • ICD/Pacemaker
    • Electrophysiology Column / Medscape
    • Contact
  • Afib
    • AFib
    • AF in Athletes
    • The best tool to treat AF
    • Know your CHADS-VASC Score
    • 3 non-warfarin anticoagulants
    • AF ablation
      • 13 things to know about AF
      • Atrial Fib Ablation -2012 Update
      • Gender-Spec results of AF ablation
    • Female gender and stroke risk in AF
    • My AF Story
  • Heart Healthy
    • Heart Disease (by DrJohnM)
    • Healthy Living
    • Exercise
    • Nutrition
    • inflammation
  • Policy
    • Policy
    • Health Care
    • Health Care Reform
  • Doctoring
    • Doctoring
    • Knowledge
    • Reflection
    • General Medicine
      • Does your cholesterol level matter?
    • General Cardiolgy – Medicine
      • What is a normal heart rate?
      • Cardiology/Internal Med
      • General Cardiology
      • Athletic heart
        • The ECG of an athlete
      • General Medicine
      • Stroke
      • Statins
  • Cycling
    • DrJohnM on Cycling
    • How I became a bike racer
    • My top 12 Likes on Cycling
    • Cyclocross
      • A CX-Primer
    • Fitness
    • Athletic heart
    • The Mysterious Athletic Heart

Big Questions with Xarelto Study

February 10, 2016 By Dr John

The purpose of this post is to introduce my most recent column over at theHeart.org | Medscape Cardiology in which I address recent concerns about the drug rivaroxaban (Xarelto).

—

In 2014, Rivaroxaban (Xarelto) was the most prescribed new oral anticoagulant (NOAC). Millions of patients have atrial fibrillation, so it’s fair to call it a blockbuster drug.

Recently, however, concerns have arisen about the validity of the results of the pivotal trial, called ROCKET-AF, that led to FDA approval. Recall that in the 14,000-patient-strong multicenter ROCKET-AF trial, rivaroxaban was found to be noninferior to warfarin for stroke prevention in patients with AF. Major bleeding rates were similar.

The new concern is that the device used to test INR levels (International Normalized Ratio levels are used to adjust warfarin dosing) in patients in the warfarin arm of ROCKET-AF is now under a Class I FDA recall. The device can give falsely now INRs in certain conditions.

This is huge because the key to a clinical trial is making sure two drugs are compared fairly. If warfarin-treated patients were managed with a faulty device, that could skew the results toward rivaroxaban.

In fact, concerns about the robustness of the warfarin arm of ROCKET-AF are not new. At the time of FDA approval, some experts cited the less than skillful use of warfarin in the trial as a reason to doubt the relative efficacy and safety of rivaroxaban.

Writing in the British Medical Journal, Deborah Cohen, an associate editor at the BMJ, makes the case that these revelations cast significant doubt on the validity of the ROCKET-AF trial. She and other experts call for independent verification of the study’s results. (You can read the letter for free; it’s written in plain language, which is striking in its effect.)

To counter these concerns, the ROCKET-AF investigators (from the Duke Clinical Research Institute) went back to their data-sheets to test whether the recalled INR device affected the results. They found that it did not. Their analysis, which was published in the New England Journal of Medicine, upheld the main results of the trial: rivaroxaban remained noninferior to warfarin for stroke prevention without an increase in major bleeding.

I have used rivaroxaban since its approval in 2011. During these years, other studies and observations have informed our experience with this drug. These studies, and my personal experience with rivaroxaban, have been positive.

In my most recent column over at theHeart.org on Medscape, I explain the concerns with ROCKET-AF, list four reasons to remain confident about rivaroxaban, and send a message to the Bayer corporation, the makers of rivaroxaban and keepers of the ROCKET-AF data.

The title of the post is: Rivaroxaban: It’s Not Time to Cut the Rope, Yet

JMM

  • Email
  • LinkedIn
  • Facebook
  • Twitter
  • More
  • Reddit

Related posts:

  1. Why don’t people ask their doctors more questions?
  2. Is this the most important cardiology study of the last decade?
  3. Update on anticoagulation for atrial fibrillation: Encouraging news for rivaroxaban (Xarelto)
  4. New post up on Trials and Fibrillations…Apixaban (Eliquis) was supposed to beat Pradaxa and Xarelto?

Filed Under: AF ablation, Atrial fibrillation, Dabigatran/Rivaroxaban/Apixaban, Doctoring, General Cardiology, General Medicine Tagged With: Rivaroxaban, Warfarin, Xarelto

John Mandrola, MD

Welcome, Enjoy, Interact. john-mandrola I am a cardiac electrophysiologist practicing in Louisville KY. I am also a husband to a palliative care doctor, a father, a bike racer, and a regular columnist at theHeart.org | Medscape

My First Book is Now Available…

Email Newsletter

Search the Site

Categories

Find me on theheart.org | Medscape Cardiology

  • Electrophysiology commentary on Medscape/Cardiology

Mandrola on Medscape

  • My Medscape column on general medical matters

For patients...Educational posts

  • 13 things to know about Atrial Fibrillation — 2014
  • A new cure of AF
  • Adding a new verb to doctoring: To deprescribe is to do a lot
  • AF ablation — 2015 A Cautionary Note
  • AF Ablation in 2012–An easier journey?
  • Atrial Flutter — 15 facts you may want to know.
  • Benign PVCs: A heart rhythm doctor’s approach.
  • Caution with early Cardioversion
  • Decisions of 2 low-risk cases of PAF
  • Defining success in AF ablation in 2014
  • Four commonly asked questions on AF ablation
  • Inflammation and AF — Get off the gas
  • Ten things to expect after AF ablation
  • The medical decsion as a gamble
  • The most important verb in our health crisis
  • Wellness Requires Ownership

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.